Upstream / Downstream
Explore pathways related to this product.
CST Antibody Performance Guarantee
Find answers on our FAQs page.
PTM information and tools available.
CREB (48H2) Rabbit mAb (Sepharose® Bead Conjugate) #3955
This product is discontinued
Gallery: CREB (48H2) Rabbit mAb (Sepharose® Bead Conjugate) #3955
CREB (48H2) Rabbit mAb (Sepharose® Bead Conjugate) detects endogenous levels of total CREB protein.
Monoclonal antibody is produced by immunizing animals with a GST-CREB full length fusion protein.
This Cell Signaling Technology (CST) antibody is immobilized via covalent binding of primary amino groups to N-hydroxysuccinimide (NHS)-activated Sepharose® beads. It is useful for the immunoprecipitation of CREB. CST expects that CREB (48H2) Rabbit mAb (Sepharose® Bead Conjugate) will display the same species cross-reactivity as the unconjugated antibody (CREB (48H2) Rabbit mAb #9197).
CREB is a bZIP transcription factor that activates target genes through cAMP response elements. CREB is able to mediate signals from numerous physiological stimuli, resulting in regulation of a broad array of cellular responses. While CREB is expressed in numerous tissues, it plays a large regulatory role in the nervous system. CREB is believed to play a key role in promoting neuronal survival, precursor proliferation, neurite outgrowth, and neuronal differentiation in certain neuronal populations (1-3). Additionally, CREB signaling is involved in learning and memory in several organisms (4-6). CREB is able to selectively activate numerous downstream genes through interactions with different dimerization partners. CREB is activated by phosphorylation at Ser133 by various signaling pathways including Erk, Ca2+, and stress signaling. Some of the kinases involved in phosphorylating CREB at Ser133 are p90RSK, MSK, CaMKIV, and MAPKAPK-2 (7-9).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc. U.S. Patent No. 5,675,063. U.S. Patent No. 5,675,063.